APP and Alzheimer disease: In an APP/PS1 transgenic AD mouse model, 10 times of intravenous injection of the nanoparticles decreased ~ 20% of the BACE1 expression, leading to reduced levels of Aβ plaques and improved cognitive capacity in AD mice without any side effects.